Janssen Pharmaceutica NV has identified interleukin-17A (IL-17A)/IL-17 receptor A (IL-17RA) interaction inhibitors reported to be useful for the treatment of psoriasis, rheumatoid arthritis, radiographic axial spondyloarthritis (ankylosing spondylitis), multiple sclerosis, asthma, chronic obstructive pulmonary disease, atopic dermatitis and systemic lupus erythematosus, among others.
McMaster University has synthesized radiolabeled-drug conjugates comprising a glutamate carboxypeptidase 2 (FOLH1; NAALAD1; PSMA)-targeting moiety covalently linked to a DNA intercalating agent through a radiolabeling moiety reported to be useful for diagnosis and treatment of cancer.
Genescience Pharmaceuticals Co. Ltd. has identified phenylalanine hydroxylase (PAH) (R408W mutant) stabilizers reported to be useful for the treatment of phenylketonuria (PKU).
Shenzhen Salubris Pharmaceuticals Co. Ltd. has synthesized compounds acting as MIR124 activators reported to be useful for the treatment of inflammatory bowel disease and inflammatory disorders.
Researchers at Dongguk University and Korean Research Institute of Bioscience and Biotechnology have described oxazole derivatives acting as malate dehydrogenase, cytoplasmic (MDH1) and/or malate dehydrogenase, mitochondrial (MDH2) inhibitors reported to be useful for the treatment of cancer.
Scientists at Beone Medicines I GmbH and Beone Pharmaceutical (Suzhou) Co. Ltd. have divulged histone acetyltransferase KAT6A (MOZ; MYST-3) and histone acetyltransferase KAT6B (MOZ2; MYST-4) inhibitors reported to be useful for the treatment of breast cancer.
RSS